Joint development strategy has been developed to address international deployment requirements if current outbreak continues or expands globally
Recent pathogens illustrate need for improved situational awareness capabilities, such as those provided by the Co-Dx PCR point-of-care platform
The Australian patent represents the first patent granted for the Company’s new point-of-care testing platform.
Co-Diagnostics Joint Venture, CoSara, Invited to Participate in 2nd Advanced TB Diagnostics Course in Chennai, India
Company forms new AI business unit, led by Chief Technology & AI Officer Christopher Thurston, to unify and advance Co-Dx’s existing and future AI initiatives
The Memorandum of Understanding includes the formation of a Joint Venture in the Kingdom of Saudi Arabia for manufacturing and distribution of the Company’s upcoming Co-Dx™ PCR platform and other Co-Dx IP
The clinical laboratory real-time PCR multiplex test was designed using Co-Dx Co-Primers™ and licensed by the CDSCO for use in diagnostic procedures
Second quarter results impacted by volume declines; Further progress on the development of the Co-Dx PCR Home platform
Co-Diagnostics announced that it will be disclosing the global expansion of its OEM agreement with Bio Molecular Systems (BMS) at the Company’s customer and distributor update today at AACC.
Co-Diagnostics announced that it has shipped testing reagents for monkeypox virus currently exhibiting a multi-country outbreak to one of its international distributors.
Co-Diagnostics announced that it has completed the principal design work of a PCR test for the monkeypox virus currently exhibiting a multi-country outbreak.
Co-Diagnostics announced that CoSara Diagnostics has received clearance by the CDSCO in India to manufacture and sell its SARAQ™ Hepatitis C Viral Load Kit as an in vitro diagnostic.